Table 6 Reporting rates of the five drug substances most frequently reported stratified by age and sex
Rank | 2 month-1 year [number of ADR reports per 100,000 drug prescriptions] a | 2–3 years [number of ADR reports per 100,000 drug prescriptions] a | 4–6 years [number of ADR reports per 100,000 drug prescriptions] a | 7–12 years [number of ADR reports per 100,000 drug prescriptions] a | 13–17 years [number of ADR reports per 100,000 drug prescriptions] a |
|---|---|---|---|---|---|
1. | topiramat: 379.4 | valproinic acid: 47.8 | oxcarbazepine: 27.9 | etanercept: 542.2 | etanercept: 505.5 |
female: 481.6 | female: 48.9 | female: 26.1 | female: 503.9 | female: 503.3 | |
male: 262.5 | male: 40.6 | male: 29.3 | male: 575.6 | male: 452.8 | |
2. | levetiracetam: 250.7 | amoxicillin: 1.3 | methylphenidate: 22.8 | insulin aspartat: 47.8 | isotretinoin: 22.5 |
female: 237.3 | female: 1.0 | female: 19.3 | female: 46.6 | female: 14.8 | |
male: 245.3 | male: 1.4 | male: 22.6 | male: 48.9 | male: 25.3 | |
3. | valproinic acid: 161.0 | cefaclor: 1.0 | valproinic acid: 19.5 | atomoxetine: 19.1 | methylphenidate: 6.0 |
female: 80.9 | female: 0.8 | female: 25.5 | female: 14.9 | female: 9.7 | |
male: 204.1 | male: 1.2 | male: 15.2 | male: 19.4 | male: 4.8 | |
4. | palivizumab: 87.7 b | salbutamol: 0.5 | amoxicillin: 0.8 | methylphenidate: 5.2 | dienogest: 4.6 |
female: 72.7 male: 88.4 | female: 0.4 male: 0.5 | female: 0.7 male: 1.0 | female: 4.9 male: 5.0 | female: 4.6 male: 0 | |
5. | ibuprofen: 0.7 | ibuprofen: 0.3 | ibuprofen: 0.3 | ibuprofen: 0.4 | levonorgestrel: 2.8 |
female: 0.5 | female: 0.2 | female: 0.2 | female: 0.2 | female: 2.8 | |
male: 0.7 | male: 0.4 | male: 0.4 | male: 0.5 | male: 0 |